OrganaBio, LLC

OrganaBio's proprietary supply chain provides our customers with mission critical resources: from birth tissue-derived progenitor and immune cells to a suite of expert services and flexible cGMP manufacturing solutions. Infrastructure and supply chain constraints consistently prevent the life sciences industry from delivering cutting-edge therapies to patients. Our company philosophy is founded on the premise that supply chain control, quality and redundancy ultimately dictate program success. Our network of physicians gives us access to fresh c-section birth tissue, allowing us to manufacture the highest-quality cellular starting materials for cell-, gene-, and immunotherapies. Through our unprecedented approach to supply chain management, we are transforming a world of cell and gene research into one of cell and gene therapies. OrganaBio was founded in 2018 through a collaborative partnership between cell therapy scientists and healthcare entrepreneurs. Fueled by youthful energy, grounded by ethical principles, and driven by a passion for helping patients, OrganaBio is creating a new paradigm among contract development and manufacturing organizations.